Autonomic dysfunction in Parkinson's disease

References

• Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO 3rd. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 133(5), 338–347 (2000).
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Sharabi Y, Karp BI et al. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin. Auton. Res. 17(2), 118–121 (2007).
   PubMed Web of Science ®Google Scholar
• Mathias CJ, Mallipeddi R, Bleasdale-Barr K. Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy. J. Neurol. 246(10), 893–898 (1999).
   PubMed Web of Science ®Google Scholar
• Senard JM, Raï S, Lapeyre-Mestre M et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 63(5), 584–589 (1997).
   PubMed Web of Science ®Google Scholar
• Lipp A, Sandroni P, Ahlskog JE et al. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch. Neurol. 66(6), 742–750 (2009).
   PubMedGoogle Scholar
• Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 75(10), 1470–1471 (2004).
   PubMed Web of Science ®Google Scholar
• Mathias CJ, Bannister R. Postprandial hypotension in autonomic disorders. In: Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Mathias CJ, Bannister R (Eds). Oxford University Press, Oxford, UK, 283–295 (2002).
   Google Scholar
• Cicconetti P, Morelli S, De Serra C et al. Left ventricular mass in dippers and nondippers with newly diagnosed hypertension. Angiology 54(6), 661–669 (2003).
   PubMed Web of Science ®Google Scholar
• Routledge F, McFetridge-Durdle J. Nondipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur. J. Cardiovasc. Nurs. 6(1), 9–26 (2007).
   PubMedGoogle Scholar
• Sommer S, Aral-Becher B, Jost W. Nondipping in Parkinson’s disease. Parkinsons. Dis. doi:10.4061/2011/897586 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Parkinson J. An Essay on the Shaking Palsy. Whittingham and Rowland, London, UK (1817).
   Google Scholar
• Eadie MJ, Tyrer JH. Alimentary disorder in parkinsonism. Australas. Ann. Med. 14, 13–22 (1965).
   PubMedGoogle Scholar
• Korczyn AD. Autonomic nervous system disturbances in Parkinson’s disease. Adv. Neurol. 53, 463–468 (1990).
   PubMedGoogle Scholar
• Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson’s disease. Mov. Disord. 6(2), 151–156 (1991).
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2(2), 107–116 (2003).
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat. Disord. 17(1), 10–15 (2011).
   PubMed Web of Science ®Google Scholar
• Jost WH. Gastrointestinal dysfunction in Parkinson’s Disease. J. Neurol. Sci. 289(1–2), 69–73 (2010).
   PubMed Web of Science ®Google Scholar
• Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson’s disease. Eur. J. Clin. Nutr. 46(12), 879–884 (1992).
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang SM, Hernán MA, Willett WC, Ascherio A. Weight loss in Parkinson’s disease. Ann. Neurol. 53(5), 676–679 (2003).
   PubMed Web of Science ®Google Scholar
• Ragonese P, D’Amelio M, Callari G et al. Body mass index does not change before Parkinson’s disease onset. Eur. J. Neurol. 15(9), 965–968 (2008).
   PubMed Web of Science ®Google Scholar
• Wang GJ, Volkow ND, Logan J et al. Brain dopamine and obesity. Lancet 357(9253), 354–357 (2001).
   PubMed Web of Science ®Google Scholar
• Wang GJ, Volkow ND, Thanos PK, Fowler JS. Imaging of brain dopamine pathways: implications for understanding obesity. J. Addict. Med. 3(1), 8–18 (2009).
   PubMed Web of Science ®Google Scholar
• Evidente VG, Caviness JN, Adler CH, Gwinn-Hardy KA, Pratley RE. Serum leptin concentrations and satiety in Parkinson’s disease patients with and without weight loss. Mov. Disord. 16(5), 924–927 (2001).
   PubMedGoogle Scholar
• Lorefält B, Toss G, Granérus AK. Weight loss, body fat mass, and leptin in Parkinson’s disease. Mov. Disord. 24(6), 885–890 (2009).
   PubMed Web of Science ®Google Scholar
• Barichella M, Cereda E, Pezzoli G. Major nutritional issues in the management of Parkinson’s disease. Mov. Disord. 24(13), 1881–1892 (2009).
   PubMed Web of Science ®Google Scholar
• Wang G, Wan Y, Cheng Q et al. Malnutrition and associated factors in Chinese patients with Parkinson’s disease: results from a pilot investigation. Parkinsonism Relat. Disord. 16(2), 119–123 (2010).
   PubMed Web of Science ®Google Scholar
• Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology 69(4), 333–341 (2007).
   PubMed Web of Science ®Google Scholar
• Müller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB; Parkwest Study Group. Autonomic and sensory symptoms and signs in incident, untreated Parkinson’s disease: frequent but mild. Mov. Disord. 26(1), 65–72 (2011).
   PubMed Web of Science ®Google Scholar
• Arbouw ME, Movig KL, Koopmann M et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 74(15), 1203–1207 (2010).
   PubMed Web of Science ®Google Scholar
• Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov. Disord. 17(6), 1318–1320 (2002).
   PubMed Web of Science ®Google Scholar
• Nóbrega AC, Rodrigues B, Melo A. Does botulinum toxin injection in parotid glands interfere with the swallowing dynamics of Parkinson’s disease patients? Clin. Neurol. Neurosurg. 111(5), 430–432 (2009).
   PubMedGoogle Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. In: Parkinson’s Disease. Ebadi M, Pfeiffer RF (Eds). CRC Press, Boca Raton, FL, USA, 259–273 (2005).
   Google Scholar
• Gross RD, Atwood CW Jr, Ross SB, Eichhorn KA, Olszewski JW, Doyle PJ. The coordination of breathing and swallowing in Parkinson’s disease. Dysphagia 23(2), 136–145 (2008).
   PubMed Web of Science ®Google Scholar
• Troche MS, Huebner I, Rosenbek JC, Okun MS, Sapienza CM. Respiratory–swallowing coordination and swallowing safety in patients with Parkinson’s disease. Dysphagia 26(3), 218–224 (2011).
   PubMed Web of Science ®Google Scholar
• Byrne KG, Pfeiffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson’s disease. A report of clinical experience at a single center. J. Clin. Gastroenterol. 19(1), 11–16 (1994).
   PubMed Web of Science ®Google Scholar
• Menezes C, Melo A. Does levodopa improve swallowing dysfunction in Parkinson’s disease patients? J. Clin. Pharm. Ther. 34(6), 673–676 (2009).
   PubMedGoogle Scholar
• Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson’s disease. N. Engl. J. Med. 346(15), 1174–1175 (2002).
   PubMed Web of Science ®Google Scholar
• Born LJ, Harned RH, Rikkers LF, Pfeiffer RF, Quigley EM. Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy. Mov. Disord. 11(1), 53–58 (1996).
   PubMed Web of Science ®Google Scholar
• Troche MS, Okun MS, Rosenbek JC et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology 75(21), 1912–1919 (2010).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kato T, Nishida H et al. Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson’s disease? An analysis using the 13C-acetate breath test. J. Neurol. 258(3), 421–426 (2011).
   PubMed Web of Science ®Google Scholar
• Goetze O, Nikodem AB, Wiezcorek J et al. Predictors of gastric emptying in Parkinson’s disease. Neurogastroenterol. Motil. 18(5), 369–375 (2006).
   PubMed Web of Science ®Google Scholar
• Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s disease. Mov. Disord. 12(6), 952–957 (1997).
   PubMed Web of Science ®Google Scholar
• Gil RA, Hwynn N, Fabian T, Joseph S, Fernandez HH. Botulinum toxin type A for the treatment of gastroparesis in Parkinson’s disease patients. Parkinsonism Relat. Disord. 17(4), 285–287 (2011).
   PubMed Web of Science ®Google Scholar
• Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom survey. Parkinsonism Relat. Disord. 8(4), 277–284 (2002).
   PubMed Web of Science ®Google Scholar
• Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson’s disease: a pilot study. Mov. Disord. 21(8), 1270–1273 (2006).
   PubMed Web of Science ®Google Scholar
• Ueki A, Otsuka M. Life style risks of Parkinson’s disease: association between decreased water intake and constipation. J. Neurol. 251(Suppl. 7), vII18–vII23 (2004).
   PubMedGoogle Scholar
• Jost WH, Schimrigk K. Constipation in Parkinson’s disease. Klin. Wochenschr. 69(20), 906–909 (1991).
   PubMedGoogle Scholar
• Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov. Disord. 12(6), 946–951 (1997).
   PubMed Web of Science ®Google Scholar
• Abbott RD, Petrovitch H, White LR et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57(3), 456–462 (2001).
   PubMed Web of Science ®Google Scholar
• Abbott RD, Ross GW, Petrovitch H et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov. Disord. 22(11), 1581–1586 (2007).
   PubMed Web of Science ®Google Scholar
• Savica R, Carlin JM, Grossardt BR et al. Medical records documentation of constipation preceding Parkinson disease: a case–control study. Neurology 73(21), 1752–1758 (2009).
   PubMed Web of Science ®Google Scholar
• Liu Z, Sakakibara R, Odaka T et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov. Disord. 20(6), 680–686 (2005).
   PubMed Web of Science ®Google Scholar
• Chiu CM, Wang CP, Sung WH, Huang SF, Chiang SC, Tsai PY. Functional magnetic stimulation in constipation associated with Parkinson’s disease. J. Rehabil. Med. 41(13), 1085–1089 (2009).
   PubMed Web of Science ®Google Scholar
• Bassotti G, Maggio D, Battaglia E et al. Manometric investigation of anorectal function in early and late stage Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 68(6), 768–770 (2000).
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Odaka T, Uchiyama T et al. Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 74(2), 268–272 (2003).
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Kishi M, Ogawa E et al. Bladder, bowel, and sexual dysfunction in Parkinson’s disease. Parkinsons. Dis. doi:10.4061/2011/924605 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: response to apomorphine. Ann. Neurol. 33(5), 490–493 (1993).
   PubMed Web of Science ®Google Scholar
• Tateno F, Sakakibara R, Yokoi Y et al. Levodopa ameliorated anorectal constipation in de novo Parkinson’s disease: the QL-GAT study. Parkinsonism Relat. Disord. 17(9), 662–666 (2011).
   PubMed Web of Science ®Google Scholar
• Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson’s disease with botulinum neurotoxin A. Am. J. Gastroenterol. 98(6), 1439–1440 (2003).
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sullivan KL, Arnulf I et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74(11), 924–931 (2010).
   PubMed Web of Science ®Google Scholar
• Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov. Disord. 21(6), 737–745 (2006).
   PubMed Web of Science ®Google Scholar
• O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov. Disord. 23(1), 101–106 (2008).
   PubMed Web of Science ®Google Scholar
• Singer C. Urological dysfunction. In: Parkinson’s Disease and Nonmotor Dysfunction. Pfeiffer RF, Bodis Wollner I (Eds). Humana Press, Totowa, NJ, USA, 139–148 (2005).
   Google Scholar
• Singer C. Urinary dysfunction in Parkinson’s disease. In: Parkinson’s Disease. Ebadi M, Pfeiffer RF (Eds). CRC Press, Boca Raton, FL, USA, 275–286 (2005).
   Google Scholar
• Appell RA. Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent. Drugs 66(10), 1361–1370 (2006).
   PubMed Web of Science ®Google Scholar
• Staskin DR, Rosenberg MT, Sand PK, Zinner NR, Dmochowski RR. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, Phase III trials. Int. J. Clin. Pract. 63(12), 1715–1723 (2009).
   PubMed Web of Science ®Google Scholar
• Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease: a review. Parkinsonism Relat. Disord. 15(2), 81–87 (2009).
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J. Urol. 182(4), 1453–1457 (2009).
   PubMed Web of Science ®Google Scholar
• Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease. Parkinsonism Relat. Disord. 16(8), 531–534 (2010).
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Conte A, Proietti S et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J. Urol. 186(3), 960–964 (2011).
   PubMed Web of Science ®Google Scholar
• Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson’s disease. J. Urol. 129(1), 80–83 (1983).
   PubMedGoogle Scholar
• Galloway NT. Urethral sphincter abnormalities in Parkinsonism. Br. J. Urol. 55(6), 691–693 (1983).
   PubMedGoogle Scholar
• Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy. J. Neurol. Neurosurg. Psychiatr. 71(5), 600–606 (2001).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Carbone A, Inghilleri M et al. Urodynamic and neurophysiological evaluation in Parkinson’s disease and multiple system atrophy. J. Neurol. Neurosurg. Psychiatr. 62(5), 507–511 (1997).
   PubMedGoogle Scholar
• Bronner G. Sexual problems in Parkinson’s disease: the multidimensional nature of the problem and of the intervention. J. Neurol. Sci. 310(1–2), 139–143 (2011).
   PubMed Web of Science ®Google Scholar
• Koller WC, Vetere-Overfield B, Williamson A, Busenbark K, Nash J, Parrish D. Sexual dysfunction in Parkinson’s disease. Clin. Neuropharmacol. 13(5), 461–463 (1990).
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Shinotoh H, Uchiyama T et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton. Neurosci. 92(1–2), 76–85 (2001).
   PubMed Web of Science ®Google Scholar
• Waters C, Smolowitz J. Impaired sexual function. In: Parkinson’s Disease and Nonmotor Dysfunction. Pfeiffer RF, Bodis-Wollner I (Eds). Humana Press, Totowa, NJ, USA, 127–137 (2005).
   Google Scholar
• Singer C, Weiner WJ, Sanchez-Ramos J, Ackerman M. Sexual function in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 54(10), 942 (1991).
   PubMed Web of Science ®Google Scholar
• Brown RG, Jahanshahi M, Quinn N, Marsden CD. Sexual function in patients with Parkinson’s disease and their partners. J. Neurol. Neurosurg. Psychiatr. 53(6), 480–486 (1990).
   PubMed Web of Science ®Google Scholar
• Bronner G, Royter V, Korczyn AD, Giladi N. Sexual dysfunction in Parkinson’s disease. J. Sex Marital Ther. 30(2), 95–105 (2004).
   PubMed Web of Science ®Google Scholar
• Welsh M, Hung L, Waters CH. Sexuality in women with Parkinson’s disease. Mov. Disord. 12(6), 923–927 (1997).
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson’s disease. Mov. Disord. 15(2), 305–308 (2000).
   PubMed Web of Science ®Google Scholar
• Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J. Neurol. Neurosurg. Psychiatr. 71(3), 371–374 (2001).
   PubMed Web of Science ®Google Scholar
• Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch. Neurol. 59(5), 807–811 (2002).
   PubMedGoogle Scholar
• Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann. Neurol. 3(2), 129–133 (1978).
   PubMed Web of Science ®Google Scholar
• den Hartog Jager WA, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J. Neurol. Neurosurg. Psychiatr. 23, 283–290 (1960).
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson’s disease. Eur. Neurol. 38(Suppl. 2), 2–7 (1997).
   PubMed Web of Science ®Google Scholar
• Beach TG, Adler CH, Sue LI et al.; Arizona Parkinson’s Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 119(6), 689–702 (2010).
   PubMedGoogle Scholar
• Turkka JT, Myllylä VV. Sweating dysfunction in Parkinson’s disease. Eur. Neurol. 26(1), 1–7 (1987).
   PubMedGoogle Scholar
• De Marinis M, Stocchi F, Testa SR, De Pandis F, Agnoli A. Alterations of thermoregulation in Parkinson’s disease. Funct. Neurol. 6(3), 279–283 (1991).
   PubMedGoogle Scholar
• Sage JI, Mark MH. Drenching sweats as an off phenomenon in Parkinson’s disease: treatment and relation to plasma levodopa profile. Ann. Neurol. 37(1), 120–122 (1995).
   PubMed Web of Science ®Google Scholar
• van Hilten BJ, Roos RA. The continuum of hyperthermic syndromes with impaired dopaminergic activity. Arch. Intern. Med. 152(8), 1727–1730 (1992).
   Google Scholar
• Reutens DC, Harrison WB, Goldswain PR. Neuroleptic malignant syndrome complicating levodopa withdrawal. Med. J. Aust. 155(1), 53–54 (1991).
   PubMedGoogle Scholar
• Pfeiffer RF, Sucha EL. “On-off”-induced lethal hyperthermia. Mov. Disord. 4(4), 338–341 (1989).
   PubMedGoogle Scholar
• Sanghera MK, Ward C, Stewart RM, Mewes K, Simpson RK, Lai EC. Alleviation of drenching sweats following subthalamic deep brain stimulation in a patient with Parkinson’s disease – a case report. J. Neurol. Sci. 285(1–2), 246–249 (2009).
   PubMed Web of Science ®Google Scholar
• Leonardi M, Raggi A, Pagani M et al. Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord. 18(1), 35–39 (2012).
   PubMed Web of Science ®Google Scholar
• Li H, Zhang M, Chen L et al. Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson’s disease. Mov. Disord. 25(16), 2740–2746 (2010).
   PubMed Web of Science ®Google Scholar
• Carter JH, Stewart BJ, Lyons KS, Archbold PG. Do motor and nonmotor symptoms in PD patients predict caregiver strain and depression? Mov. Disord. 23(9), 1211–1216 (2008).
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov. Disord. 25(15), 2493–2500 (2010).
   PubMed Web of Science ®Google Scholar
• Lebouvier T, Neunlist M, Bruley des Varannes S et al. Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS ONE 5(9), e12728 (2010).
   PubMed Web of Science ®Google Scholar
• Lebouvier T, Tasselli M, Paillusson S, Pouclet H, Neunlist M, Derkinderen P. Biopsable neural tissues: toward new biomarkers for Parkinson’s disease? Front. Psychiatry 1, 128 (2010).
   PubMedGoogle Scholar
• Shannon KM, Keshavarzian A, Mutlu E et al. Alpha-synuclein in colonic submucosal in early untreated Parkinson’s disease. Mov. Disord. doi:10.1002/mds.23898 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci. Lett. 396(1), 67–72 (2006).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Prusiner SB. Is Parkinson’s disease a prion disorder? Proc. Natl Acad. Sci. USA 106(31), 12571–12572 (2009).
   PubMed Web of Science ®Google Scholar
• Jang H, Boltz D, Sturm-Ramirez K et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc. Natl Acad. Sci. USA 106(33), 14063–14068 (2009).
   PubMed Web of Science ®Google Scholar
• Henry J, Smeyne RJ, Jang H, Miller B, Okun MS. Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism Relat. Disord. 16(9), 566–571 (2010).
   PubMed Web of Science ®Google Scholar
• Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces Parkinson’s disease gastrointestinal neuropathology. Neurobiol. Dis. 36(1), 96–102 (2009).
   PubMed Web of Science ®Google Scholar